Harm reduction refers to strategies that aim to reduce the harms associated with injecting drug use.1
The earliest forms of harm reduction promoted abstinence from drug use and put reducing its occurrence at the centre of substance use policy and interventions.2
The concept of harm reduction was re-invented in the early 1980s at the beginning of the HIV epidemic when healthcare workers started to provide clean syringes to people who inject drugs (sometimes referred to as PWID) rather than solely trying to achieve abstinence.3
Since then, there has been slow but steady progress in implementing harm reduction programmes as a component of the response to the HIV epidemic, with a wide range of initiatives tried to datein a variety of settings.4 5
However, of the 158 countries that report drug use, only 91 of them explicitly reference harm reduction in their national policies (58%).6 Moreover, few countries have achieved sufficient coverage of harm reduction services.
The World Health Organization (WHO), the United Nations Office on Drugs and Crime (UNODC) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) strongly recommend harm reduction as an approach to HIV prevention, treatment and care for people who inject drugs. Specifically, they advocate for a comprehensive package including:
- needle and syringe programmes (NSPs)
- opioid substitution therapy (OST) and other drug dependence treatment
- HIV testing and counselling (HTC)
- antiretroviral treatment (ART)
- prevention and treatment of sexually transmitted infections (STIs)
- condom programmes for people who inject drugs and their sexual partners
- targeted information, education and communication for people who inject drugs and their sexual partners
- vaccination, diagnosis and treatment of viral hepatitis
- prevention, diagnosis and treatment of tuberculosis (TB).7
Impact of harm reduction on HIV
Worldwide, the benefits of harm reduction have been proven. Early implementers of harm reduction programmes such as Switzerland, the UK and Australia have reduced the number of new HIV infections among people who inject drugs to practically zero.8
More recently, the government of Nepal cut the HIV prevalence among people who inject drugs from 68% in 2002 to 6.3% in 2011 by scaling up its harm reduction programme. Likewise, the implementation of harm reduction programmes in Xichang City in China cut the number of new HIV cases among people who inject drugs by 75%. 9
Since 2008, HIV prevalence among people who inject drugs in Ukraine has more than halved with the roll-out of harm reduction programmes. In contrast, the same period saw a surge in HIV prevalence among people who inject drugs, from 1% to 41.6%, in the Philippines where there has been little implementation of harm reduction programmes. 10
Case study: Harm reduction in Ukraine
In Ukraine the first harm reduction programmes were introduced in 2004. Since then there has been a significant expansion of harm reduction services with more than 212,800 people who inject drugs reached in 2015 and more than 19 million syringes distributed. During this period national HIV prevalence rates have reduced dramatically – falling from 41.8% in 2008 to 19.7% in 2014.
Despite this success harm reduction services in Ukraine are at risk. Support from the Global Fund, on which these services rely, is scheduled to end in 2017 and at present there is no government funding available to plug this gap.
Cost effectiveness of harm reduction programmes
Research has shown that harm reduction programming is cost-effective. For example, in Australia every dollar invested in needle and syringe programmes (NSPs) returned four dollars in healthcare savings. A study carried out across eight countries in Eastern Europe and Central Asia found that investments in NSPs returned savings of between 1.6 and 2.7 times the original investment by preventing HIV and hepatitis C infections. [11
Types of harm reduction programmes
Needle and syringe programmes (NSPs)
Needle and syringe programmes (NSPs) allow people who inject drugs to obtain new, sterile needles and other drug paraphernalia at little or no cost to reduce the risk of HIV infection. NSPs have the added bonus of preventing the transmission of other blood-borne viruses such as hepatitis B and C.12
NSPs can also serve as a crucial gateway to other HIV services. People who inject drugs engage with NSPs on a consistent basis creating a number of opportunities to provide access to other forms of relevant healthcare such as opioid substitution therapy (OST), HIV testing and counselling (HTC), and treatment for HIV, tuberculosis (TB) and hepatitis.13
NSPs can be delivered through a range of means including pharmacies, vending machines and outreach services.14 With high incarceration levels among people who inject drugs, access to sterile injecting equipment and NSP services are a vital component of healthcare in prisons.15
In 2014, NSPs were available in 90 countries worldwide.16
Opioid substitution therapy (OST)
Opioid substitution therapy (OST) is the practice of replacing an illegal opiate (such as heroin) with a prescribed medicine such as methadone or buprenorphine that are typically administered under medical supervision.17 In 2014, 79 countries were implementing OST.18
In many places, OST has proved highly effective in reducing injecting drug use behaviours among opioid-dependent people, limiting their risk of HIV transmission.19 20Providing sufficient access to OST could prevent 130,000 new HIV infections outside sub-Saharan Africa every year. 21
OST has also been found to improve access and adherence to ART, reduce instances of overdosing and associated mortality, lessen criminal activity and more generally, improve the physical and mental health of people who injects drugs.22 23 24 OST has also been found to reduce the risk of HIV transmission from pregnant women dependent upon drugs to their infants.25
The benefits of OST have been demonstrated in developing countries as well as developed ones. One study reported average treatment retention of 70% across Asia, Eastern Europe, the Middle East and Oceania. All countries also saw reductions in opioid use, HIV risk behaviour, criminal activity as well as improvements in general wellbeing.26
However, studies have found a difference in adherence between those on methadone and those on buprenorphine. For example, one randomised trial reported a 76% completion rate among those on methadone compared to 46% among those taking buprenorphine. It also found that sexual risk behaviours decreased equally among women on both treatment regimes but increased for men on BUP and decreased for men on MET.27
Despite evidence of the effectiveness of OST, 78 countries and territories that report injecting drug use did not have such programmes in place in 2014. Since 2012, only two countries (Burkina Faso and Turkey) have newly implemented OST. Twenty-five countries have scaled up OST provision, but Estonia, Lithuania, Serbia, Mexico and Australia have decreased provision.28
In some countries, including Switzerland, Austria and Slovenia, patients are treated with slow-release morphine as an alternative to methadone. Slow-release morphine has been found to be at least as effective as methadone in treating people dependent on opioids.29 30
Drug consumption rooms
Drug consumption rooms allow people who inject drugs to inject under medical supervision. They enable an immediate response to overdosing and decrease the transmission of blood-borne diseases such as HIV through access to sterile injecting equipment and education on safe injection practices. They can also provide access to healthcare as well as HTC.31
To date, evidence regarding the effectiveness of drug consumption rooms as a method of reducing HIV transmission is limited. However, they are known to be effective in increasing uptake of detoxification and treatment services.32
As of 2014, there were 88 drug consumption rooms worldwide, although only two of these were outside of Europe (one in Canada and one in Australia).33
Case study: Insite, Canada
In 2003, Insite in Vancouver became North America's first drug consumption room. Since its inception, the facility has been a source of controversy between the government and public health researchers.34
In 2008, the facility was threatened with closure under drug trafficking and possession laws. However, a ruling by the Supreme Court of British Columbia said that Canada’s Controlled Drugs and Substances Act violated an individual's constitutional rights:
"It denies the addict access to a health care facility where the risk of morbidity associated with infectious disease is diminished, if not eliminated…While there is nothing to be said in favour of the injection of controlled substances that leads to addiction, there is much to be said against denying addicts health care services that will ameliorate the effects of their condition." 35
In 2013, new legislation again threatened the existence of Insite and other proposed drug consumption rooms in the country.36 In contrast, a 2012 report highlighted the need for a similar facility in Toronto based on positive results from Insite. Since its launch, uptake of OST has increased by 42% with the fatal overdose rate falling by 35%.37
An estimated 70,000 – 100,000 people die due to opioid overdose each year.38 Naloxone is an opiate antagonist that reverses the effects of an opioid overdose. Its use in drug consumption rooms is increasingly effective, as immediate administration by supervisors reduces overdose deaths, and encourages future attendance at drug consumption rooms.39 By controlling the harm caused by injecting drugs in a safe environment, the risks of HIV transmission are lessened.
One study in Sydney, Australia found that the opening of just one drug consumption room that offered supervised injections and naloxone for overdoses, significantly decreased the burden on the local ambulance service.40
The need for access to naloxone to be scaled up is more pressing than ever. Combining this with effective behaviour change communication, clean needles and OST potentially has a huge public health benefit.41
Other drug dependence treatment
Other interventions are recommended where non-opioid drugs such as amphetamines, cocaine, sedatives and hypnotics are highly used and where OST remains unavailable.
Drug dependence treatment helps prevent HIV transmission by reducing the sharing of needles and syringes and high-risk sexual behaviours associated with drug intoxication as well as providing HIV education and other HIV-related healthcare.42
For example, cognitive behavioural interventions, a type of counselling which focuses on changing patterns of thinking and behaviour, have been shown to decrease amphetamine use.43 Likewise, medically supervised drug withdrawal (detoxification) can assist with the withdrawal process as well as reduce the discomfort of withdrawal when used in conjunction with OST.44 45
Pharmacy sale of syringes
Many argue that pharmacies are an important but under-utilised resource in preventing the transmission of HIV and other blood-borne infections among people who inject drugs. Pharmacists are some of the most accessible healthcare professionals and are in an ideal position to reach this group who are often socially marginalised and wish to remain anonymous.46
Pharmacists can fulfil a number of harm reduction roles including the sale of condoms, educating on safer sex practice, selling clean needles and syringes and dispensing oral methadone for opioid dependence.47
Research has shown how the sale of over-the-counter syringes to people who inject drugs can reduce HIV prevalence among this group. One study of 96 metropolitan areas in the USA recorded an average HIV prevalence of 13.8% among people who inject drugs in areas with anti-over-the-counter laws compared to 6.7% across areas without such laws.48
A different study from Tallinn, Estonia, reported that people who inject drugs found pharmacies convenient for acquiring syringes due to their extended opening hours and local setting. However, some reported stigma and discrimination from both pharmacists and other customers, with the idea of distributing free syringes to people who inject drugs negatively received by some pharmacists.49
Safer crack smoking resources
Smoking drugs can lead to open sores, burns or cuts on the lips and in the mouth. Blood from these wounds can contaminate the ‘stem’ - usually a small metal pipe - and be passed on to the next smoker. If two smokers both have open sores then there is a risk of HIV transmission.50
As a result, some harm reduction agencies have distributed 'safe crack kits' to reduce the sharing of pipes and the use of broken ones. Like other harm reduction programmes, they enable drug users to access the appropriate healthcare and support.51
One study from Vancouver found that 12 months after kit distribution, 79% and 59% of recipients used supplied items such as mouthpieces and condoms respectively. However, while access to these specific safer use items increased noticeably, the impact of the kits on wider safer use practice was limited.52
Amphetamine harm reduction initiatives
Amphetamines cause an elevated sex drive, and there is evidence of an increase in unprotected sex among people taking the drug. This is most commonly reported among men who have sex with men, transgender people, sex workers, and among attendees of ‘chem-sex’ parties predominately in European cities. As a result, the risk of HIV transmission from amphetamine-fuelled unprotected sex is rising.53
Unlike opiates, there are currently no drug dependency treatments for amphetamines, although trials are on-going.54
Peer and community-led provision of harm reduction services has been proven to increase the uptake of these services in a variety of countries and settings.
Case study: Peer-led harm reduction
In one district in Vietnam where 75% of the people living with HIV were people who inject drugs, programming moved from a traditional approach (using behaviour change communication, commodities provision and voluntary counselling and testing referral) to a peer-driven intervention approach with web-based outreach.
Two outreach workers (one from an HIV outpatient clinic and one from a methadone maintenance therapy clinic) recruited people who inject drugs, providing them with 'coupons' and other incentives and referrals for HIV testing services (and, where necessary, care and treatment). These initial recruits (or 'seeds') pass coupons to other people in their own networks, including other people who inject drugs and their sexual partners.
The programme resulted in improvements in tracking people through services, and increases in testing and diagnosis—from 94 people tested (3.2% of whom tested positive) in 2013 to 483 people (6.8% of whom tested positive) in 2015. In 2016, of the 10.9% of people tested who were living with HIV, 41.6% were enrolled in treatment. 55
Barriers to harm reduction for HIV prevention
Harm reduction has been demonstrated as both an effective and efficient way of preventing the transmission of HIV and other blood-borne viruses among drug users. However, a number of barriers prevent its implementation.
Stigma, discrimination and the war on drugs
A 'war on drugs' approach still prevails in many countries. Law enforcement authorities continue to criminalise the possession of needles and syringes and mount 'crackdowns' on people who inject drugs even when they are seeking treatment or visiting healthcare centres for clean needles and syringes or other services. Criminalisation drives people who inject drugs away from health and HIV services.56
In 2014, the UN Committee on Economic, Social and Cultural Rights raised concerns with Ukraine about “the punitive approach taken in the State party towards persons who use drugs, which results in high numbers of such persons being imprisoned”.57
Stigma and discrimination in healthcare centres also has the same effect. As well as having a detrimental impact upon people receiving treatment, stigma and discrimination later impacts upon those in the recovery process who may be drug-free but are still subject to prejudice in areas such as employment because of their history of drug use. Many advocate for stigma reduction initiatives as part of harm reduction programmes.58
The harm reduction funding crisis
International donors provide the majority of financial resources for harm reduction programmes to prevent HIV, with the Global Fund the single largest funder in this area.61 However, many middle-income countries where most of the people who inject drugs live, do not qualify for Global Fund support.62 63
At last estimate in 2010, international donors spent just US$ 160 million on HIV prevention programmes for people who inject drugs - 7% of US$ 2.3 billion required.64 By contrast, around US$ 100 billion is spent annually on global drug enforcement and control. Shifting just 2.5% of this money away from drug enforcement to harm reduction programmes could reduce new HIV infections among people who inject drugs by 78%, alongside a 65% drop in HIV-related deaths by 2030. 65
Changing priorities in international policy
Approximately 75% of people who inject drugs live in middle-income countries. However, international donor policies are changing, with funds increasingly directed towards low-income countries with bigger, more generalised HIV epidemics. This disregards the lack of commitment of national governments to harm reduction policy and funding in many middle-income countries.66
Among bilateral donors, the UK Department for International Development has reduced funding for HIV by £75 million 2010 and 2014. This amounted to a 90% drop in UK bilateral support for harm reduction.67
Limited provision in prisons
The provision of harm reduction programmes remains extremely limited in prisons and other closed settings. In 2014, 43 countries were providing OST in prisons, while only eight countries were implementing NSPs in closed settings.68
The lack of NSP services is particularly concerning because of the high rates of injecting drug use and the complex interaction of HIV, hepatitis and TB in prisons worldwide.69
Photo credit: Photo by Kaytee Riek/CC BY-NC-SA 2.0
- 1. Harm Reduction International (IHRA) (2010) 'What is Harm Reduction? A position statement from the International Harm Reduction Association'
- 2. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2010) 'Harm reduction: evidence, impacts and challenges, Chapter 4: Perspectives on harm reduction - what the experts have to say'
- 3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2010) 'Harm reduction: evidence, impacts and challenges, Chapter 4: Perspectives on harm reduction - what the experts have to say'
- 4. Ti, L. and Kerr, T. (2014) 'The impact of harm reduction on HIV and illicit drug use' Harm Reduction Journal 11(7)
- 5. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2010) 'Harm reduction: evidence, impacts and challenges, Chapter 4: Perspectives on harm reduction - what the experts have to say'
- 6. Harm Reduction International (2016) 'The Case for a Harm Reduction Decade: Progress, potential and paradigm shifts'
- 7. World Health Organisation (WHO), United Nations Office on Drugs and Crime (UNODC) & UNAIDS (2009) 'Technical Guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users'
- 8. Harm Reduction International (2016) 'The Case for a Harm Reduction Decade: Progress, potential and paradigm shifts'
- 9. Harm Reduction International (2016) 'The Case for a Harm Reduction Decade: Progress, potential and paradigm shifts'
- 10. Harm Reduction International (2016) 'The Case for a Harm Reduction Decade: Progress, potential and paradigm shifts'
- 11. Harm Reduction International (2016) 'The Case for a Harm Reduction Decade: Progress, potential and paradigm shifts'
- 12. Hagan, H. et al (2011) 'A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs' The Journal of Infectious Diseases 204(1):74-83
- 13. World Health Organisation (WHO) (2004) 'Policy Brief: Provision of Sterile Injecting Equipment to Reduce HIV Transmission'
- 14. World Health Organisation (WHO), United Nations Office on Drugs and Crime (UNODC) & UNAIDS (2012) 'Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users'
- 15. World Health Organisation (WHO) (2013) 'Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection'
- 16. Harm Reduction International (IHRA) (2015) ‘The Global State of Harm Reduction Report 2014’
- 17. World Health Organisation (WHO) (2011) 'Opioid substitution therapy in resource-poor settings'
- 18. Harm Reduction International (IHRA) (2015) ‘The Global State of Harm Reduction Report 2014’
- 19. Degenhardt, L. et al (2010) 'Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed' The Lancet 376(9737):285-301
- 20. Gowling, L. et al (2008) 'Substitution treatment of injecting opioid users for prevention of HIV infection' The Cochrane Database of Systematic Reviews 16(2):CD004145
- 21. UNAIDS (2016) The Prevention Gap Report
- 22. World Health Organisation (WHO) (2013) 'Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection'
- 23. Spire, B. et al (2007) 'Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST)' The International Journal on Drug Policy 18(4):262-270
- 24. Tenore, P.L. (2008) 'Psychotherapeutic benefits of opioid agonist therapy' Journal of Addicted Diseases 27(3):49-65
- 25. Jones, H.E. et al (2001) 'The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women' Drug and Alcohol Dependence 61(3):297-306
- 26. Lawrinson, P. et al (2008) 'Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS' Addiction 103(9):1484-1492
- 27. Woody, G. E. et al (2014) 'HIV Risk Reduction With Buprenorphine-Naloxone or Methadone: Findings From a Randomized Trial 'Journal of Acquired Immune Deficiency Syndromes' 66(3):288-293
- 28. Harm Reduction International (IHRA) (2015) ‘The Global State of Harm Reduction Report 2014’
- 29. Beck, T. et al (2014) 'Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone' Addiction 109(4):617-626
- 30. Hammig, R. et al (2014) 'Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence' Journal of Substance Abuse Treatment 47(4):275-281
- 31. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2015) 'Drug consumption rooms: an overview of provision and evidence'
- 32. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2010) 'Harm reduction: evidence, impacts and challenges'
- 33. Harm Reduction International (IHRA) (2015) ‘The Global State of Harm Reduction Report 2014’
- 34. Webster, P.C. (2013) 'Canada proposes new legal hurdles for supervised injection' The Lancet 382(9903):1477-1478
- 35. Supreme Court of British Columbia (2008) 'PHS Community Services Society v. Attorney General of Canada'
- 36. Webster, P.C. (2013) 'Canada proposes new legal hurdles for supervised injection' The Lancet 382(9903):1477-1478
- 37. Marshall, B.D. et al (2011) 'Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study' Lancet 377(9775):1429-1437
- 38. UNAIDS (2016) The Prevention Gap Report
- 39. Harm Reduction International (IHRA) (2015) ‘The Global State of Harm Reduction Report 2014’
- 40. Salmon, A. M., et al (2010) ‘The impact of a supervised injection facility on ambulance call-outs in Sydney, Australia' Addiction 105(4):676-683
- 41. Centers for Disease Control and Prevention (CDC) (2016, 1 January) ‘Increases in Drug and Opioid Overdose Deaths – United States, 2000-2014’ Morbidity and Mortality Weekly Report (MMWR) 64(50):1378-1382
- 42. Sorensen, J.L. and Copeland, A.L. (2000) 'Drug abuse treatment as an HIV prevention strategy: a review' Drug and Alcohol Dependence 59(1):17-31
- 43. Baker, A. et al (2005) 'Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction' Addiction 100(3):367-378
- 44. World Health Organisation (WHO) (2009) 'Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence'
- 45. National Institute on Drug Abuse (2009) 'I principles of drug addiction treatment: A research-based guide'
- 46. Watson, T. et al (2012) 'Pharmacists and harm reduction: A review of current practices and attitudes' Canadian Pharmacists Journal 145(3):124-127
- 47. Watson, T. et al (2012) 'Pharmacists and harm reduction: A review of current practices and attitudes' Canadian Pharmacists Journal 145(3):124-127
- 48. Friedman, S.R. et al (2001) 'Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence' American Journal of Public Health 91(5):791-793
- 49. Vorobjov, S. et al (2009) 'Should Pharmacists have a Role in Harm Reduction Services for IDUs? A Qualitative Study in Tallinn, Estonia' Journal of Urban Health 86(6):918-928
- 50. Open Society Foundations (2014) 'Why Does Vancouver Need a Crack Pipe Vending Machine?' (Accessed 10/18/2016)
- 51. CATIE (2011) 'Safer crack smoking'
- 52. Malchy, L.A. et al (2011) 'Do Crack Smoking Practices Change With the Introduction of Safer Crack Kits?' Canadian Journal of Public Health 102(3):188-192
- 53. Harm Reduction International (2015) ‘A Global Review of the Harm Reduction Response to Amphetamines: A 2015 Update’
- 54. Harm Reduction International (2015) ‘A Global Review of the Harm Reduction Response to Amphetamines: A 2015 Update’
- 55. UNAIDS (2016) The Prevention Gap Report
- 56. Bearn, J. (2014) 'Harm Reduction in Substance Use and High-Risk Behaviour' The British Journal of Psychiatry 204(2):165
- 57. Harm Reduction International (IHRA) (2015) ‘The Global State of Harm Reduction Report 2014’
- 58. US Department of Health and Human Services (2009) 'Guiding Principles and Elements of Recovery-Oriented Systems of Care'
- 59. STOPAIDS & Harm Reduction International (2014) 'Factsheet: Harm reduction'
- 60. Harm Reduction International (IHRA) (2015) ‘The Global State of Harm Reduction Report 2014’
- 61. UNAIDS (2013) 'Global Report 2013'
- 62. Bridge, J. et al (2012) 'Global Fund investments in harm reduction from 2002 to 2009' The International Journal on Drug Policy 23(4):279-285
- 63. Eurasian Harm Reduction Network (2012) 'Quitting While Not Ahead: The Global Fund’s retrenchment and the looming crisis for harm reduction in Eastern Europe & Central Asia'
- 64. Harm Reducation International (IHRA) (2014) 'The funding crisis for harm reduction: Donor retreat, government neglect and the way forward'
- 65. Harm Reduction International (2016) ‘The Case for a Harm Reduction Decade: Progress, potential and paradigm shifts’
- 66. Harm Reduction International (IHRA) (2015) ‘The Global State of Harm Reduction Report 2014’
- 67. STOPAIDS (2014) Increasing DFID’s contribution to addressing HIV among key populations
- 68. Harm Reduction International (IHRA) (2015) ‘The Global State of Harm Reduction Report 2014’
- 69. United Nations Office on Drugs and Crime (UNODC) (2014) 'World Drug Report 2014'